Cargando…

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies

BACKGROUND: The aim of this study was to assess the diagnostic performance of an autoantibody battery in patients receiving immune checkpoint inhibitors who experienced immune-related adverse events (irAEs). METHODS: We retrospectively analyzed several variables potentially related to irAEs, namely,...

Descripción completa

Detalles Bibliográficos
Autores principales: Les, Iñigo, Martínez, Mireia, Narro, Alicia, Pérez, Inés, Sánchez, Cristina, Puntí, Laura, Anaut, Pilar, Eguiluz, Saioa, Herrera, Alberto, Domínguez, Severina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172225/
https://www.ncbi.nlm.nih.gov/pubmed/34060971
http://dx.doi.org/10.1080/07853890.2021.1931956
_version_ 1783702500037099520
author Les, Iñigo
Martínez, Mireia
Narro, Alicia
Pérez, Inés
Sánchez, Cristina
Puntí, Laura
Anaut, Pilar
Eguiluz, Saioa
Herrera, Alberto
Domínguez, Severina
author_facet Les, Iñigo
Martínez, Mireia
Narro, Alicia
Pérez, Inés
Sánchez, Cristina
Puntí, Laura
Anaut, Pilar
Eguiluz, Saioa
Herrera, Alberto
Domínguez, Severina
author_sort Les, Iñigo
collection PubMed
description BACKGROUND: The aim of this study was to assess the diagnostic performance of an autoantibody battery in patients receiving immune checkpoint inhibitors who experienced immune-related adverse events (irAEs). METHODS: We retrospectively analyzed several variables potentially related to irAEs, namely, demographic, clinical, and laboratory characteristics, including an autoantibody battery (antinuclear, anti-neutrophil cytoplasmic, anti-thyroid antibodies and rheumatoid factor). RESULTS: Sixty-nine patients (48 men; 61.8 ± 10.9 years at baseline) diagnosed with stage-4 solid-organ cancer and treated with nivolumab were followed up for 12 ± 10.3 months. Thirty-two irAEs were detected in 26 patients (37.5%). Adverse events occurred more commonly in women (62% vs. 27%, p = .006), and younger patients (irAEs: 58.1 ± 9.8, no irAEs: 64.1 ± 10.9 years, p = .024). Autoantibody battery results were available for 26 patients and were more frequently positive in patients with irAEs (87% vs. 30%, p = .009). The positive predictive value, negative predictive value, and diagnostic accuracy of the battery were 82.3%, 77.8%, and 80.8%, respectively. Among the 64 patients with an evaluable response, 23 (38.5%) experienced tumour progression, this being less frequent in patients with irAEs (19% vs. 48.5%, p = .03). Overall survival was higher in patients developing irAEs (HR = 1.88, p = .05). CONCLUSION: Positivity in a readily available autoantibody battery may be associated with the occurrence of irAEs. KEY MESSAGES: Positivity in an accessible and inexpensive autoantibody battery including antinuclear, anti-neutrophil cytoplasmic, anti-thyroid antibodies and rheumatoid factor may be associated with the occurrence of immune-related adverse events. Patients with cancer on immune checkpoint inhibitors experiencing immune-related adverse events showed a lower risk of progression and better overall survival than patients not experiencing this type of adverse effect.
format Online
Article
Text
id pubmed-8172225
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-81722252021-06-10 Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies Les, Iñigo Martínez, Mireia Narro, Alicia Pérez, Inés Sánchez, Cristina Puntí, Laura Anaut, Pilar Eguiluz, Saioa Herrera, Alberto Domínguez, Severina Ann Med Immunology BACKGROUND: The aim of this study was to assess the diagnostic performance of an autoantibody battery in patients receiving immune checkpoint inhibitors who experienced immune-related adverse events (irAEs). METHODS: We retrospectively analyzed several variables potentially related to irAEs, namely, demographic, clinical, and laboratory characteristics, including an autoantibody battery (antinuclear, anti-neutrophil cytoplasmic, anti-thyroid antibodies and rheumatoid factor). RESULTS: Sixty-nine patients (48 men; 61.8 ± 10.9 years at baseline) diagnosed with stage-4 solid-organ cancer and treated with nivolumab were followed up for 12 ± 10.3 months. Thirty-two irAEs were detected in 26 patients (37.5%). Adverse events occurred more commonly in women (62% vs. 27%, p = .006), and younger patients (irAEs: 58.1 ± 9.8, no irAEs: 64.1 ± 10.9 years, p = .024). Autoantibody battery results were available for 26 patients and were more frequently positive in patients with irAEs (87% vs. 30%, p = .009). The positive predictive value, negative predictive value, and diagnostic accuracy of the battery were 82.3%, 77.8%, and 80.8%, respectively. Among the 64 patients with an evaluable response, 23 (38.5%) experienced tumour progression, this being less frequent in patients with irAEs (19% vs. 48.5%, p = .03). Overall survival was higher in patients developing irAEs (HR = 1.88, p = .05). CONCLUSION: Positivity in a readily available autoantibody battery may be associated with the occurrence of irAEs. KEY MESSAGES: Positivity in an accessible and inexpensive autoantibody battery including antinuclear, anti-neutrophil cytoplasmic, anti-thyroid antibodies and rheumatoid factor may be associated with the occurrence of immune-related adverse events. Patients with cancer on immune checkpoint inhibitors experiencing immune-related adverse events showed a lower risk of progression and better overall survival than patients not experiencing this type of adverse effect. Taylor & Francis 2021-06-01 /pmc/articles/PMC8172225/ /pubmed/34060971 http://dx.doi.org/10.1080/07853890.2021.1931956 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Immunology
Les, Iñigo
Martínez, Mireia
Narro, Alicia
Pérez, Inés
Sánchez, Cristina
Puntí, Laura
Anaut, Pilar
Eguiluz, Saioa
Herrera, Alberto
Domínguez, Severina
Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
title Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
title_full Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
title_fullStr Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
title_full_unstemmed Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
title_short Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
title_sort association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172225/
https://www.ncbi.nlm.nih.gov/pubmed/34060971
http://dx.doi.org/10.1080/07853890.2021.1931956
work_keys_str_mv AT lesinigo associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies
AT martinezmireia associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies
AT narroalicia associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies
AT perezines associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies
AT sanchezcristina associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies
AT puntilaura associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies
AT anautpilar associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies
AT eguiluzsaioa associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies
AT herreraalberto associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies
AT dominguezseverina associationofimmunerelatedadverseeventsinducedbynivolumabwithabatteryofautoantibodies